Skip to search formSkip to main contentSkip to account menu

CSL112

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

High Density Lipoproteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Investigational drugs in phase II clinical trials for acute coronary syndromes
ABSTRACT Introduction: Despite current guideline-based, secondary prevention strategies in patients with the acute coronary… 
2018
2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that… 
2015
2015
It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
Clinical intervention studies have provided clear evidence that low‐density lipoproteins are causally involved in the development… 
2015
2015
Abstract 17135: Distribution of Anti-oxidative Activity During Remodeling of High Density Lipoprotein: Studies With CSL112
We have previously shown that reconstituted HDL has the ability to inactivate phospholipid hydroperoxides (PLOOH) in oxidized LDL… 
2014
2014
Abstract 15370: Mechanism of High Density Lipoprotein Remodeling Induced by CSL112
Introduction: CSL112 is apolipoprotein A-I (apoA[[Unable to Display Character: ‐]]I) purified from human plasma and reconstituted… 
2013
2013
Infusion of CSL112, a novel formulation of human apolipoprotein A-I, in healthy subjects removes tissue cholesterol and directs its clearance
Purpose: The ability of HDL to promote cholesterol efflux from atherosclerotic plaque is thought to underpin its potential for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)